Assessment of the Pharmacokinetics, Disposition, and Duration of Action of the Tumour-Targeting Peptide CEND-1

Assessment of the Pharmacokinetics, Disposition, and Duration of Action of the Tumour-Targeting Peptide CEND-1

CEND-1 (iRGD) is a bifunctional cyclic peptide that can modulate the solid tumour microenvironment, enhancing the delivery and therapeutic index of co-administered anti-cancer agents. This study explored CEND-1’s pharmacokinetic (PK) properties pre-clinically and clinically, and assessed CEND-1 dist...

Full description

Bibliographic Details
Main Authors: Harri A. Järveläinen, Christian Schmithals, Maike von Harten, Bianca Kakoschky, Thomas J. Vogl, Stephen Harris, Claire Henson, Gemma Bullen-Clerkson, Albrecht Piiper
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:International Journal of Molecular Sciences
Subjects:
CEND-1
iRGD peptide
LSTA1
certepetide
pharmacokinetics
quantitative whole-body autoradiography (QWBA)
Online Access:https://www.mdpi.com/1422-0067/24/6/5700

Internet

https://www.mdpi.com/1422-0067/24/6/5700

Similar Items